(from left to right) Dr Alap Gandhi, Country Medical Director of GSK Malaysia and Brunei; Ruxandra Nastasa, Vice President & General Manager of GSK Malaysia & Brunei; and Dr Peter Ch’ng, Consultant Dermatologist from Gleneagles Hospital Kuala Lumpur & Honorary Secretary of Dermatological Society of Malaysia at the launch of GSK’s Shingles vaccine.
GlaxoSmithKline (GSK) has launched its Herpes Zoster vaccine, Shingrix (RZV), in Malaysia. This non-live, recombinant subunit adjuvanted vaccine is intended for adults aged 50 and over, and those at increased risk of shingles and post-herpetic neuralgia.
Shingrix is administered in two doses and has shown up to 97% efficacy in preventing shingles in clinical trials. The vaccine aims to address the painful effects of shingles, which result from the reactivation of the varicella zoster virus. GSK’s Country Medical Director, Dr. Alap Gandhi, emphasized the importance of the vaccine in reducing the burden of this disease.
Read More Business News
CIMB Islamic contributes RM500,000 to UPSI Edu-Forest project supporting biodiversity conservation, research, education and Orang…
− Sandoz Malaysia has partnered with Sunway Medical Centre to expand patient access to biosimilarsthrough education and…
Raw IoT data is often just noise. AI turns this data into "actionable wisdom," explains.
Scoot has ordered 11 Airbus A320neo aircraft to enhance its fleet, supporting growth and improving…
The FBM KLCI shows positive movement, with expectations to range between 1,755-1,765, driven by anticipated…
CIMB Group appointed Mak Joon Nien as CEO of Growth Markets and CEO of CIMB…
This website uses cookies.